Get the Stockscreener App
0.3457
6.84%
-0.0254
After Hours:
.35
0.0043
+1.24%
Context Therapeutics Inc stock is traded at $0.3457, with a volume of 1.32M.
It is down -6.84% in the last 24 hours and down -20.60% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.3711
Open:
$0.3712
24h Volume:
1.32M
Relative Volume:
0.58
Market Cap:
$31.76M
Revenue:
-
Net Income/Loss:
$-40.23M
P/E Ratio:
-0.8087
EPS:
-0.4275
Net Cash Flow:
$-34.82M
1W Performance:
-6.09%
1M Performance:
-20.60%
6M Performance:
-87.05%
1Y Performance:
-61.72%
1-Day Range:
$0.3445
$0.3802
1-Week Range:
$0.3445
$0.3967
52-Week Range:
$0.3434
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.3457 | 31.76M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics (NASDAQ:CNTX) Share Price | RNS News, Quotes, & Charts | CNTX | - Proactive financial news
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
CNTX Stock Price, Quote & Chart - ChartMill
CNTX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEstimate Revision Count - dars.gov.et
Knight Therapeutics: Business Profile and TSX Market Context - Kalkine Media
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in Nectin-4-Positive Tumors - GenomeWeb
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 - marketscreener.com
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid Tumors - Quiver Quantitative
A cancer treatment enters human testing for three cancers - Stock Titan
Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? - simplywall.st
Context Therapeutics (CNTX) Edges Up 1.56% as Stock Holds Above $0.37 SupportRisk Reward Setups - vinanet.vn
Context (CNTX) Q2 2026 Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Stock Move: The Market Price Declines 3.77% in the Latest SessionEstimate Revision Count - vinanet.vn
Context Therapeutics Inc. Revenue Breakdown – NASDAQ:CNTX - tradingview.com
Context (CNTX) Q2 2026 Results: The Available Earnings Metric Delivers a Miss for This Review; Post-Report: Shares Finish 2.19% Up on the DayNext Quarter Guidance - vinanet.vn
Context (CNTX) Quarterly Figures: EPS Comes in Below Forecast for This Review; Post-Earnings: Shares Fall 1.81% - vinanet.vn
Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
a2026mar-contextxcorpdec.htm - SEC.gov
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote & History - Yahoo Finance
CNTX Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Climb 7.77%Revenue Growth Outlook - dars.gov.et
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Context Therapeutics (CNTX) Slips 6.6% to $0.45, Pressing Key Support at $0.43Factor Rotation - dars.gov.et
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Hold Rating, Announces Target Price $2 - Moomoo
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context drops bispecific T-cell engager on cost-cutting initiative - Yahoo Finance
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - marketbeat.com
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Context Therapeutics (CNTX) Advances 2.93% as Biotech Tests Key $0.65 Resistance ZoneMonthly Profile - vinanet.vn
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Enterprise value to revenue forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A - Stock Titan
CNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherEarnings Decline Risk - careplusvn.com
Context Therapeutics (CNTX) Tests Key Support Level After 4.37% DeclineNegative Gamma - dars.gov.et
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):